The Impact of HIV Infection on Eosinophil Levels during Pregnancy: A Narrative Review

Article *in* Haematology International Journal · February 2024

DOI: 10.23880/hij-16000229

2 authors:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,329 PUBLICATIONS **8,468** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University (KIU)
321 PUBLICATIONS **2,310** CITATIONS
SEE PROFILE

MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Haematology International Journal
ISSN: 2578-501X

The Impact of HIV Infection on Eosinophil Levels during Pregnancy: A Narrative Review

Emmanuel Ifeanyi Obeagu[1]* and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda
[2]School of Nursing Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com; obeagu.emmanuel@kiu.ac.ug

Review Article
Volume 8 Issue 1
Received Date: January 25, 2024
Published Date: February 09, 2024
DOI: 10.23880/hij-16000229

Abstract

Human Immunodeficiency Virus (HIV) infection poses unique challenges during pregnancy, affecting maternal health and potentially impacting the developing fetus. This systematic review explores the intricate relationship between HIV and eosinophils, a critical component of the immune system, during pregnancy. As HIV induces immunosuppression, understanding its specific effects on eosinophil levels is crucial for predicting maternal health outcomes and vertical transmission risks. The review also delves into the potential influence of antiretroviral therapy on modulating eosinophil function. By synthesizing existing literature, this review aims to provide a comprehensive understanding of the complex interplay between HIV infection, eosinophils, and pregnancy, offering insights for future research directions and potential therapeutic interventions.

Keywords: HIV Infection; Eosinophils; Pregnancy; Immunosuppression; Maternal Health; Vertical Transmission; Antiretroviral Therapy; Chemokines

Abbreviations: HIV: Human Immunodeficiency Virus; ART: Antiretroviral Therapy; CD4+: Clusters of Differentiation-4.

Introduction

Human Immunodeficiency Virus (HIV) infection continues to be a global public health concern, affecting millions of individuals worldwide. Among the diverse population impacted by HIV, pregnant women represent a particularly vulnerable group, as the virus not only poses risks to maternal health but also raises concerns regarding vertical transmission to the developing fetus. An intricate web of interactions exists between HIV and various components of the immune system, including eosinophils, which play a pivotal role in immune defense mechanisms [1-9]. Pregnancy itself is a state of immune modulation, characterized by a delicate balance between tolerance to the developing fetus and defense against potential pathogens [10-14]. Eosinophils, traditionally recognized for their role in parasitic infections and allergic responses, have emerged as key contributors to this delicate equilibrium during pregnancy. Their involvement in tissue repair, infection control, and immune regulation makes understanding their behavior in the context of HIV-infected pregnancies crucial for unraveling the complexities of maternal-fetal immune dynamics [15-24].

The purpose of this review is to comprehensively examine the impact of HIV infection on eosinophil levels during pregnancy. We aim to synthesize current knowledge on the subject, exploring how HIV-induced immunosuppression

may alter eosinophil function and subsequently influence maternal health outcomes. Additionally, we will investigate the potential ramifications of these alterations on the risk of vertical transmission, providing insights into the broader implications for the health of the developing fetus. As the global healthcare community continually strives to improve outcomes for HIV-positive pregnant women, this review seeks to contribute valuable insights into the dynamic interplay between HIV infection and eosinophils during pregnancy. By delineating the existing knowledge gaps and suggesting avenues for future research, we aim to facilitate the development of targeted interventions, ultimately enhancing the quality of care for this vulnerable population [25-29].

Immunomodulation in HIV Infection

HIV primarily targets CD4+ T cells, the central orchestrators of the immune response. The virus enters these cells, leading to their depletion and functional impairment. This depletion weakens the overall immune response, leaving the host susceptible to opportunistic infections and impairing the ability to mount effective immune defenses [30-38]. Innate immune cells, including eosinophil's, are essential for the first line of defense against infections. HIV can directly influence the function of innate immune cells through various mechanisms, such as interfering with pattern recognition receptors and altering cytokine profiles. This dysregulation contributes to the overall immunosuppressive environment characteristic of HIV infection [39-48]. Eosinophils, traditionally associated with allergic responses and parasitic infections, play a multifaceted role in immune modulation [48]. Their ability to release cytokines, chemokines, and various immune mediators positions them as key contributors to the intricate balance of immune responses during pregnancy. However, the impact of HIV on eosinophil function is not fully understood [49-54]. Studies suggest that HIV-induced immune dysregulation may extend to eosinophils, potentially altering their function during pregnancy [55-58]. Changes in eosinophil chemotaxis, degranulation, and cytokine production have been observed, highlighting a potential link between HIV infection and eosinophil dysfunction [59-62].

Eosinophils in Pregnancy

During normal pregnancy, there is a gradual increase in circulating eosinophils. This physiological eosinophilia is believed to be a response to the dynamic alterations in hormonal and immune profiles associated with gestation. The reasons behind this elevation are not fully understood but may relate to the immunomodulatory requirements of a successful pregnancy [63-67]. Beyond their historical association with allergic reactions, eosinophils actively modulate immune responses. They release an array of cytokines, chemokines, and growth factors, influencing the behavior of other immune cells. This immunomodulatory role is particularly relevant in the unique immunological environment of pregnancy [68-70]. Eosinophils are implicated in tissue repair and remodeling processes, playing a vital role in maintaining the integrity of various organs [71]. In pregnancy, this function becomes paramount for the adaptive changes occurring in the uterus and other maternal tissues to support fetal development [72-76]. Eosinophils contribute to the defense against infections, especially those caused by parasitic organisms. This protective function becomes crucial during pregnancy, as the maternal immune system needs to strike a delicate balance between tolerance to the semi-allogeneic fetus and protection against potential pathogens.

Eosinophils have been implicated in promoting immune tolerance, a key aspect of a successful pregnancy [77]. By modulating the activity of other immune cells and influencing the cytokine milieu, eosinophils contribute to the establishment and maintenance of a tolerogenic environment necessary for fetal development [78-81]. The immunomodulatory effects of HIV on eosinophils may compromise their normal functions during pregnancy. Understanding how HIV-induced changes in eosinophil behavior may impact the delicate immune balance is crucial for predicting maternal health outcomes and potential risks to the developing fetus [82-86].

Maternal Health Outcomes

HIV-infected pregnant women face an elevated risk of opportunistic infections due to compromised immune function. Eosinophils, known for their role in protecting against infections, may experience alterations in function during HIV infection. This compromised eosinophil function could contribute to an increased susceptibility to various pathogens, further challenging maternal health [87-92]. The dysregulation of immune responses in HIV-infected pregnancies can lead to heightened inflammatory states, potentially contributing to pregnancy-related complications such as preterm birth and low birth weight. Understanding the role of eosinophils in modulating inflammation during pregnancy is crucial for assessing the risk of these complications in HIV-positive women [93-98]. Eosinophils contribute to immune homeostasis during pregnancy, helping to balance the maternal immune system's responses. Any disruption in eosinophil function, as observed in HIV-infected individuals, may tilt this delicate balance, potentially impacting the overall health of pregnant women [99-106]. The introduction of antiretroviral therapy (ART) has

significantly improved maternal outcomes in HIV-infected pregnancies [107]. However, the potential interplay between ART, eosinophils, and maternal health outcomes requires careful consideration. Understanding how ART influences eosinophil function is essential for optimizing therapeutic strategies and ensuring positive maternal health outcomes [108-111] maternal health outcomes are intricately linked to the risk of vertical transmission of HIV to the fetus. Alterations in eosinophil function may influence the likelihood of viral transmission during pregnancy and childbirth. Exploring this relationship is crucial for developing targeted interventions to reduce the risk of vertical transmission [112-114].

Opportunistic Infections

HIV weakens the immune system, making pregnant individuals more susceptible to opportunistic infections. Common opportunistic infections in people with HIV include tuberculosis, pneumonia, and fungal infections. Opportunistic infections can have adverse effects on both maternal and fetal health. Management often involves a combination of antiretroviral therapy (ART) and specific treatments for the opportunistic infections [82-86].

Inflammatory States

HIV infection is associated with chronic inflammation. Persistent immune activation and inflammation can contribute to various health issues. Chronic inflammation may play a role in adverse pregnancy outcomes, including preterm birth and low birth weight. Managing inflammation is an essential aspect of HIV care during pregnancy [99-106].

Pregnancy-Related Complications

Pregnant individuals with HIV may face an increased risk of certain complications, including preterm birth, low birth weight, and preeclampsia. Without proper management, there is a risk of mother-to-child transmission of HIV during pregnancy, childbirth, or breastfeeding. Antiretroviral medications, elective cesarean delivery, and avoiding breastfeeding in certain situations can help reduce transmission risks [108-111].

Antiretroviral Therapy (ART)

Initiating and maintaining ART during pregnancy is crucial for preventing mother-to-child transmission of HIV and improving maternal health. Healthcare providers closely monitor the health of pregnant individuals with HIV, adjusting ART regimens as needed to optimize both maternal and fetal outcomes [112-114].

Postpartum Considerations

Postpartum care is crucial for both maternal and infant health. Continued use of ART and monitoring for potential complications is important during the postpartum period [107].

Vertical Transmission Risk

Eosinophils, traditionally recognized for their role in combating infections, may serve as guardians against vertical transmission. Their involvement in the defense against various pathogens, including certain viruses, prompts exploration into whether alterations in eosinophil function impact the likelihood of vertical transmission of HIV. HIV infection is known to induce immunosuppression and may disrupt the normal functioning of eosinophils. Understanding these HIV-induced changes in eosinophil behavior is crucial, as any compromise in their ability to protect against infections could potentially elevate the risk of vertical transmission. Antiretroviral therapy (ART), a cornerstone in preventing mother-to-child transmission of HIV, may have implications for eosinophil function. Investigating the interplay between ART, eosinophils, and the risk of vertical transmission provides insights into how therapeutic interventions may influence the maternal-fetal transmission dynamic [115-118].

Eosinophils contribute to immune modulation, influencing the overall immune environment during pregnancy. Any alterations in this immune modulation, particularly in the context of HIV infection, may impact the intricate balance required to prevent the transmission of the virus to the developing fetus [119]. The placenta, a critical interface between the maternal and fetal circulations, plays a pivotal role in vertical transmission. Exploring how eosinophils interact with other immune cells at this interface and understanding their role in preventing or facilitating viral transmission is essential for deciphering the dynamics of mother-to-child HIV transmission. Insights into the relationship between eosinophils and vertical transmission risk can inform the development of targeted strategies to mitigate this risk. Understanding how eosinophils contribute to the prevention of viral transmission offers potential avenues for therapeutic interventions aimed at enhancing maternal-fetal health.

Antiretroviral Therapy (ART) and Eosinophil Levels

The primary goal of ART is to suppress viral replication, reducing the viral load in the maternal bloodstream. As viral replication diminishes, the immune system, including

eosinophils, may experience a degree of restoration. Understanding the kinetics of this restoration is vital for evaluating its implications on maternal-fetal immune dynamics [119]. Eosinophil levels in peripheral blood serve as a potential surrogate marker for immune modulation. Monitoring changes in eosinophil counts can offer insights into the broader immune response to ART. Investigating the correlation between viral suppression, immune reconstitution, and eosinophil levels provides a comprehensive view of the therapeutic impact [118]. While ART primarily targets viral replication, its effects on immune cells, including eosinophils, are multifaceted. Studies suggest that ART may have immunomodulatory effects, influencing the function and activation of eosinophils. A nuanced understanding of these effects is essential for predicting how ART may impact the overall immune landscape during pregnancy [111].

Eosinophils contribute to immune homeostasis, and alterations in their function may have implications for maternal health. Assessing how ART-induced changes in eosinophil behavior influence the susceptibility to infections and the overall well-being of HIV-positive pregnant women is crucial for optimizing maternal care [119]. Understanding the impact of ART on eosinophils extends to their role at the maternal-fetal interface. As the placenta represents a critical site for immune interactions, investigating how ART influences eosinophil behavior in this context provides insights into the potential effects on vertical transmission risk. Insights into the interplay between ART, eosinophils, and maternal health outcomes pave the way for optimizing therapeutic strategies. Tailoring ART regimens to not only achieve viral suppression but also to support immune modulation, including eosinophil function, is crucial for enhancing the overall success of HIV-infected pregnancies.

Goals of ART in relation to eosinophil levels

Antiretroviral therapy (ART) is the cornerstone of treatment for HIV infection. The primary objective of ART is to suppress the replication of the HIV virus, reducing viral load to undetectable levels. Achieving viral suppression helps in preserving immune function, including eosinophil function. Controlling HIV replication supports the overall stability of the immune system. ART aims to restore and maintain the immune system, specifically CD4 T-cell counts. Eosinophils, as part of the immune system, can be affected by HIV-induced immunosuppression. Immune restoration through ART contributes to the normalization of eosinophil levels. By maintaining effective immune function, ART helps prevent opportunistic infections, including those affecting eosinophil levels. Opportunistic infections can lead to alterations in eosinophil levels. Preventing these infections supports the proper functioning of eosinophils and other immune cells. ART can help reduce chronic inflammation associated with HIV infection. Chronic inflammation can affect the overall immune environment, potentially influencing eosinophil function. ART's anti-inflammatory effects contribute to maintaining a balanced immune response. In pregnant individuals with HIV, ART is crucial for preventing mother-to-child transmission and improving maternal health. By optimizing maternal health, including immune function, ART indirectly contributes to favorable eosinophil levels during pregnancy [108-117].

Controversies or Challenges associated with using ART in the context of Eosinophil Function

In some individuals starting ART, there can be an exaggerated inflammatory response called immune reconstitution inflammatory syndrome. Eosinophils may be involved in the inflammatory response associated with IRIS. The management involves careful monitoring and sometimes anti-inflammatory treatments. Some antiretroviral drugs may have side effects or interactions that can influence immune responses. While direct effects on eosinophil function may not be well-documented, monitoring for drug-related complications and adjusting treatment when necessary is essential. Adherence to ART regimens is crucial for treatment success, but issues such as pill burden and side effects can impact adherence. Poor adherence can lead to treatment failure, potentially impacting immune function, including eosinophil levels. Some studies have explored potential associations between certain antiretrovirals and adverse pregnancy outcomes. The impact of these controversies on eosinophil function specifically may not be well-established, but careful consideration is necessary in pregnant individuals [116-119].

Recommendations

Longitudinal studies tracking eosinophil levels throughout the course of HIV-infected pregnancies, from preconception to postpartum, are essential. This approach will enable a comprehensive assessment of how eosinophil dynamics correlate with viral load, immune reconstitution, and maternal-fetal outcomes. Investigating eosinophil infiltration into the placenta and their interactions with other immune cells at the maternal-fetal interface is crucial. This research can enhance our understanding of the role eosinophils play in protecting against vertical transmission and guide interventions to mitigate the risk. Further exploration of how eosinophils contribute to immune tolerance during pregnancy, particularly in the context of HIV infection, is warranted. Understanding the balance between immune responses against potential pathogens and

tolerance to the semi-allogeneic fetus is crucial for predicting maternal health outcomes.

Clinical trials should be conducted to optimize ART regimens specifically considering their impact on immune modulation, including eosinophil function. Tailoring ART to support immune reconstitution and balance the delicate immune landscape during pregnancy can potentially enhance therapeutic efficacy. Implementing integrated care models that incorporate obstetric, infectious disease and immunology expertise can improve the overall management of HIV-infected pregnant women. Such models should consider both virological and immunological aspects, ensuring a holistic approach to maternal-fetal health. Recognizing the psychosocial impact of HIV infection during pregnancy is crucial. Integrating comprehensive psychosocial support, including counseling and mental health services, into routine antenatal care can improve maternal well-being and positively influence pregnancy outcomes.

Ongoing education and training programs for healthcare professionals involved in the care of HIV-infected pregnant women are essential. Keeping healthcare providers abreast of the latest research findings and guidelines ensures that evidence-based practices are consistently applied, optimizing maternal and fetal health outcomes. Engaging communities in understanding and addressing the unique challenges faced by HIV-positive pregnant women fosters a supportive environment. Community empowerment initiatives can reduce stigma, enhance adherence to care, and improve overall maternal health. Facilitating global collaboration and knowledge exchange among researchers, healthcare professionals, and policymakers is critical. Sharing experiences and best practices on a global scale can accelerate progress in the field, ultimately benefiting HIV-infected pregnant women worldwide.

Conclusion

The intersection of Human Immunodeficiency Virus (HIV) infection, eosinophils, and pregnancy represents a multifaceted landscape that continues to challenge researchers, healthcare professionals, and policymakers alike. This comprehensive review has delved into the intricate relationship between HIV and eosinophils during pregnancy, aiming to shed light on the impact of this interplay on maternal and fetal health. Maternal health outcomes in HIV-infected pregnancies are intricately linked to altered eosinophil function, potentially affecting susceptibility to infections and contributing to inflammatory states. The risk of vertical transmission adds another layer of concern, necessitating a nuanced understanding of how HIV, eosinophils, and therapeutic interventions collectively influence the maternal-fetal transmission dynamic.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU (2022) Under-Nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences 2(3): 120-127.

2. Obeagu EI, Alum EU, Obeagu GU (2023) Factors Associated with Prevalence of HIV among Youths: A Review of Africa Perspective. Madonna University journal of Medicine and Health Sciences 3(1): 13-18.

3. Obeagu EI (2023) A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences 3(1): 7-12.

4. Obeagu EI, Obeagu GU (2023) An Update on Premalignant Cervical Lesions and Cervical Cancer Screening Services among HIV Positive Women. Journal of Public Health and Nutrition 6(2): 141.

5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, et al. (2021) Prevalence of Malaria with Anaemia and HIV Status in Women of Reproductive Age in Onitsha, Nigeria. Journal of Pharmaceutical Research International 33(4): 10-19.

6. Omo Emmanuel UK, Chinedum OK, Obeagu EI (2017) Evaluation of Laboratory Logistics Management Information System in HIV/AIDS Comprehensive Health Facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci 3(1): 21-38.

7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO (2023) Factors Contributing to Low Utilization of HIV Counseling and Testing Services. Int J Curr Res Med Sci 9(2): 1-5.

8. Obeagu EI, Obeagu GU (2022) An Update on Survival of People Living with HIV in Nigeria. Journal of Public Health and Nutrition 5(6): 129.

9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, et al. (2021) Facilitators and Barriers to Retention in HIV Care among HIV Infected MSM Attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International 33(52B): 10-19.

10. Obeagu EI, Agreen FC (2023) Anaemia among Pregnant Women: A Review of African Pregnant Teenagers. J Pub Health Nutri 6(1): 138.

11. Obeagu EI, Ezimah AC, Obeagu GU (2016) Erythropoietin

in the Anaemias of Pregnancy: A Review. Int J Curr Res Chem Pharm Sci 3(3): 10-18.

12. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, et al. (2021) Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci 9(4): 145-148.

13. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences 6(2): 10-13.

14. Jakheng SP, Obeagu EI (2022) Seroprevalence of Human Immunodeficiency Virus based on Demographic and Risk Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri 5(6): 127.

15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, et al. (2020) TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International 32(22): 101-109.

16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC (2016) Determination of Haematocrit Level and Iron Profile study among Persons Living with HIV in Umuahia, Abia State, Nigeria. J Bio Innov 5(4): 464-471.

17. Ifeanyi OE, Obeagu GU (2015) The Values of Prothrombin Time among HIV Positive Patients in FMC Owerri. Int J Curr Microbiol App Sci 4(4): 911-916.

18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, et al. (2016) Knowledge of Preventive Measures and Management of HIV/AIDS Victims among Parents in Umuna Orlu Community of Imo state Nigeria. Int J Adv Res Biol Sci 3(10): 55-65.

19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, et al. (2017) HIV and TB Co-infection among Patients who used Directly Observed Treatment Short-course Centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci 12(4): 70-75.

20. Oloro OH, Oke TO, Obeagu EI (2022) Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences 2(3): 110-119.

21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, et al. (2016) Change in Lipid Peroxidation Marker (MDA) and Non-enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J Bio Innov 5(1): 24-30.

22. Igwe CM, Obeagu IE, Ogbuabor OA (2022) Clinical Characteristics of People Living with HIV/AIDS on ART in 2014 at Tertiary Health Institutions in Enugu, Nigeria. Journal of Public Health and Nutrition 5(6): 130.

23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI (2015) The Values of Activated Partial Thromboplastin Time (APTT) among HIV Positive Patients in FMC Owerri. Int J Curr Res Aca Rev 3(4): 139-144.

24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO (2018) Hematological Indices o HIV Seropositive Subjects in Nnamdi Azikiwe University Teaching Hospital (NAUTH), Nnewi. Ann Clin Lab Res 6(1): 221.

25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF (2017) Impact of Prevention of Mother to Child Transmission (PMTCT) of HIV on Positivity Rate in Kafanchan, Nigeria. Int J Curr Res Med Sci 3(2): 28-34.

26. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI (2023) Alarming Rise in HIV Cases in Pakistan: Challenges and Future Recommendations at Hand. Health Sci Rep 6(8): e1450.

27. Obeagu EI, Amekpor F, Scott GY (2023) An Update of Human Immunodeficiency Virus Infection: Bleeding Disorders. J Pub Health Nutri 6(1): 139.

28. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, et al. (2022) Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences 2(3): 128-134.

29. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL (2022) Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International 34(3A): 29-34.

30. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, et al. (2020) Cascade Variabilities in TB Case finding among people living with HIV and the use of IPT: Assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International 32(24): 9-18.

31. Obeagu EI, Obeagu GU (2023) A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int J Adv Res Biol Sci 10(9): 135-142.

32. Obeagu EI, Onuoha EC (2023) Tuberculosis among HIV Patients: A Review of Prevalence and Associated Factors. Int J Adv Res Biol Sci 10(9): 128-134.

33. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP (2017) Haematological Indices of Malaria Patients Coinfected with HIV in Umuahia. Int J Curr Res Med Sci 3(5): 100-104.

34. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, et al. (2022) Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology 13(2): 26-31.

35. Viola N, Kimono E, Nuruh N, Obeagu EI (2023) Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences 3(2): 7-14.

36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N (2020) Comparative Study of Enzyme linked Immunosorbent Assay (Elisa) and Rapid Test Screening Methods on HIV, Hbsag, Hcv and Syphilis among Voluntary Donors in Owerri, Nigeria. J Clin Commun Med 2(3): 180-183.

37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, et al. (2021) Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International 33(47A): 78-84.

38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K (2023) Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth 6(1): 203-211.

39. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, et al. (2022) Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases 10(4): 1-7.

40. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC (2021) Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International 33(57A): 360-368.

41. Igwe MC, Obeagu EI, Ogbuabor AO (2022) Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids in Tertiary Health Institutions in Enugu State. Madonna University Journal of Medicine and Health Sciences 2(3): 42-57.

42. Madekwe CC, Madekwe CC, Obeagu EI (2022) Inequality of Monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University Journal of Medicine and Health Sciences 2(3): 6-15.

43. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, et al. (2023) Weights of Infants Born to Hiv Infected Mothers: A Prospective Cohort Study in Federal Medical Centre, Owerri, Imo State. European Journal of Pharmaceutical and Medical Research 10(8): 564-568.

44. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, et al. (2015) Biochemical Alterations in Adult Hiv Patients on Antiretrqviral Therapy. World Journal of Pharmacy and Pharmaceutical Sciences 4(3): 153-160.

45. Obeagu EI, Obeagu GU (2015) Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int J Curr Res Biosci Plant Biol 2(4): 45-49.

46. Obeagu EI, Nwosu DC (2019) Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. Int J Curr Res Chem Pharm Sci 6(12): 45-48.

47. Obeagu EI, Scott GY, Amekpor F, Obeagu GU (2023) Implications of CD4/CD8 Ratios in Human Immunodeficiency Virus Infections. Int J Curr Res Med Sci 9(2): 6-13.

48. Obeagu EI, Ochei KC, Okeke EI, Anode AC (2016) Assessment of the Level of Haemoglobin and Erythropoietin in Persons Living with HIV in Umuahia. International Journal of Medicine Research 1(2): 28-30.

49. Long H, Liao W, Wang L, Lu Q (2016) A Player and Coordinator: The Versatile Roles of Eosinophils in the Immune System. Transfusion Med Hemother 43(2): 96-108.

50. Ifeanyi OE, Obeagu GU (2015) The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int J Curr Microbiol App Sci 4(4): 906-910.

51. Obeagu EI, Okeke EI, Anonde Andrew C (2016) Evaluation of Haemoglobin and Iron Profile Study among Persons Living with HIV in Umuahia, Abia state, Nigeria. Int J Curr Res Biol Med 1(2): 1-5.

52. Alum EU, Ugwu OP, Obeagu EI, Okon MB (2023) Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences 3(2): 28-31.

53. Obeagu EI, Obeagu GU, Paul-Chima UO (2023) Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy 3(2): 64-67.

54. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB (2023) HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences 3(2): 95-99.

55. Mkhize-Kwitshana ZL, Taylor M, Jooste P, Mabaso ML, Walzl G (2011) The Influence of Different Helminth Infection Phenotypes on Immune Responses against HIV in Co-infected adults in South Africa. BMC Infectious Diseases 11: 273.

56. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF (2022) Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences 2(2): 1-9.

57. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU (2022) Evaluation of Protein C, Protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences 2(1): 292-298.

58. Obeagu EI, Obeagu GU, Adepoju OJ (2022) Evaluation of Haematological Parameters of Pregnant Women based on Age Groups in Olorunsogo Road Area of Ido, Ondo State. J Bio Innov 11(3): 936-941.

59. Obeagu EI (2022) An Update on Utilization of Antenatal Care among Pregnant Women in Nigeria. Int J Curr Res Chem Pharm Sci 9(9): 21-26.

60. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI (2018) A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research 1(2): 8-14.

61. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB (2014) Assessment of Some Haematological and Biochemical Parametrs in HIV Patients before Receiving Treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci 5: 825-830.

62. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC (2014) Pattern of Total White Blood Cell and Differential Count Values in HIV Positive Patients Receiving Treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research 3(1): 186-189.

63. Okoroiwu IL, Obeagu EI, Obeagu GU (2022) Determination of Clot Retraction in Preganant Women Attending Antenatal Clinic in Federal Medical Centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences 2(2): 91-97.

64. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ (2021) Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science 9(12): 462-464.

65. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, et al. (2022) ABO Blood Groups and Gestational Diabetes among Pregnant Women Attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology 5(2): 159-167.

66. Obeagu EI (2023) Gestational Thrombocytopaenia. J Gynecol Women's Health 25(3): 556163.

67. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obsterics Characteristics that Effect the Newborn Outcomes. Int J Adv Res Biol Sci 10(3): 134-143.

68. Obeagu EI, Ogunnaya FU (2023) Pregnancy Induced Haematological Changes: A Key to Marternal and Child Health. European Journal of Biomedical 10(8): 42-43.

69. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, ey al. (2017) Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research 5(4): 206.

70. Kita H (2011) Eosinophils: Multifaceted Biological Properties and Roles in Health and Disease. Immunol Rev 242(1): 161-77.

71. Eze RI, Obeagu EI, Edet FN (2021) Frequency of Rh Antigen C and C among Pregnant Women in Sub-Urban area in Eastern Nigeria. Madonna Uni J Med Health Sci 1(1): 19-30.

72. Obeagu EI, Ofodile AC, Okwuanaso CB (2023) A Review of Urinary Tract Infections in Pregnant Women: Risks Factors. J Pub Health Nutri 6(1): 137.

73. Obeagu EI, Obeagu GU, Musiimenta E (2023) Post-partum Haemorrhage among Pregnant Women: Update on Risks Factors. Int J Curr Res Med Sci 9(2): 14-17.

74. Obeagu EI, Obeagu GU, Ogunnaya FU (2023) Deep Vein Thrombosis in Pregnancy: A Review of Prevalence and Risk Factors. Int J Curr Res Chem Pharm Sci 10(8): 14-21.

75. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, et al. (2022) Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. International Journal of Research and Reports in Gynaecology 5(1): 222-229.

76. Orefice R (2021) Immunology and the Immunological Response in Pregnancy. Best Pract Res Clin Obstet Gynaecol 76: 3-12.

77. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA (2018) Assessment of Some Haematological Parameters in Malaria Infected Pregnant Women in Imo State Nigeria. Int J Curr Res Biol Med 3(9): 1-4.

78. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF (2017) Prevalence of Asymptomatic Bacteriuria and its Antibiotic Susceptibility Pattern in Pregnant Women Attending Private Ante Natal Clinics in Umuahia Metropolitan. Int J Curr Res Biol Med 2(2): 13-23.

79. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, et al. (2021) Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International 33(27A): 36-43.

80. Obeagu EI, Njar VE, Obeagu GU (2023) Infertility: Prevalence and Consequences. Int J Curr Res Chem Pharm Sci 10(7): 43-50.

81. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM (2021) Evaluation of Levels of Some Inflammatory Cytokines in Preeclamptic Women in Owerri. Journal of Pharmaceutical Research International 33(42A): 53-65.

82. Oloro OH, Obeagu EI (2022) A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research 10(5): 1-11.

83. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, et al. (2015) Alterations in Superoxide Dismutiase, Vitamins C and E in HIV Infected Children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences 2(11): 268-271.

84. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV Resistance in Patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES) 3(2): 56-59.

85. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC (2018) Vitamin D and Insulin Resistance in HIV Sero Positive Individuals in Umudike. Int J Curr Res Med Sci 4(2): 104-108.

86. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK (2018) A Review on Blood Borne Viral Infections: Universal Precautions. Int J Adv Res Biol Sci 5(6): 60-66.

87. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS (2018) Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord 1(2).

88. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA (2023) Translation of HIV/AIDS Knowledge into Behavior Change among Secondary School Adolescents in Uganda: A Review. Medicine (Baltimore) 102(49): e36599.

89. Obeagu EI, Faduma MH, Uzoma G (2023) Ectopic Pregnancy: A Review. Int J Curr Res Chem Pharm Sci 10(4): 40-44.

90. Obeagu EI, Gamade SM, Obeagu GU (2023) The Roles of Neutrophils in Pregnancy. Int J Curr Res Med Sci 9(5): 31-35.

91. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, et al. (2021) Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. Journal of Pharmaceutical Research International 33(30A): 67-71.

92. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI (2023) Distribution of ABO and Rhesus Blood Grouping with HIV Infection among Blood Donors in Ekiti State Nigeria. Medicine (Baltimore) 102(47): e36342.

93. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI (2023) Effect of Dolutegravir Regimen against other Regimens on some Hematological Parameters, CD4 Count and Viral Load of People living with HIV Infection in South Eastern Nigeria. Medicine (Baltimore) 102(47): e35910.

94. Opeyemi AA, Obeagu EI (2023) Regulations of Malaria in Children with Human Immunodeficiency Virus Infection: A Review. Medicine (Baltimore) 102(46): e36166.

95. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, et al. (2023) Inclusion of Nutritional Counseling and

Mental Health Services in HIV/AIDS Management: A Paradigm Shift. Medicine (Baltimore) 102(41): e35673.

96. Obeagu EI, Obeagu GU (2023) Molar Pregnancy: Update of Prevalence and Risk Factors. Int J Curr Res Med Sci 9(7): 25-28.

97. Obeagu EI, Bunu UO (2023) Factors that Influence Unmet Need for Family Planning. International Journal of Current Research in Biology and Medicine 8(1): 23-27.

98. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, et al. (2017) Barriers to Utilization of Maternal Health Services in Southern Senatorial District of Cross Rivers State, Nigeria. Int J Adv Multidiscip Res 4(8): 1-9.

99. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA (2018) Assessment of Coagulation Parameters in Malaria Infected Pregnant Women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences 4(9): 41-49.

100. Obeagu EI, Obeagu GU (2023) Postpartum Haemorrhage among Women Delivering through Spontaneous Vaginal Delivery: Prevalence and Risk Factors. Int J Curr Res Chem Pharm Sci 10(8): 22-26.

101. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC (2022) Zinc Level in Apparently Pregnant Women in Urban Area. Madonna University journal of Medicine and Health Sciences 2(1): 134-148.

102. Ogomaka IA, Obeagu EI (2021) Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International 33(41B): 380-386.

103. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, et al. (2023) Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS) 3(3).

104. Obeagu EI, Ubosi NI, Uzoma G (2023) Storms and Struggles: Managing HIV Amid Natural Disasters. Int J Curr Res Chem Pharm Sci 10(11): 14-25.

105. Obeagu EI, Obeagu GU (2023) Human Immunodeficiency Virus and Tuberculosis infection: A Review of Prevalence of Associated Factors. Int J Adv Multidiscip Res 10(10): 56-62.

106. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, et al. (2023) Reducing HIV Infection Rate in Women: A Catalyst to Reducing HIV Infection Pervasiveness in Africa. International Journal of Innovative and Applied Research 11(10): 1-6.

107. Stringer EM, Kendall MA, Lockman S, Campbell TB, Nielsen-Saines K, et al. (2018) Pregnancy Outcomes among HIV-infected Women who Conceived on Antiretroviral Therapy. PLoS One 13(7): e0199555.

108. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC (2023) Sickle Cell Anaemia: A Gestational Enigma. European Journal of Biomedical and Pharmaceutical Sciences 10(9): 72-75.

109. Ifeanyi OE, Uzoma OG (2018) A Review on Erythropietin in Pregnancy. J Gynecol Womens Health 8(3): 1-4.

110. Ifeanyi OE (2018) A Review on Pregnancy and Haematology. Int J Curr Res Biol Med 3(5): 26-28.

111. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh (2015) Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review 3(5): 376-383.

112. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, et al. (2017) Factors that Influence Women's Utilization of Primary Health Care Services in Calabar Cros River State, Nigeria. Int J Curr Res Chem Pharm Sci 4(7): 28-33.

113. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A (2021) Evaluation of Iron Status and Some Haematological Parameters of Pregnant Women in Enugu, South Eastern Nigeria. World Journal of Pharmaceutical and Medical Research 7(5): 251-254.

114. Limou S, Winkler CA, Wester CW (2019) HIV Pharmacogenetics and Pharmacogenomics: From Bench to Bedside. Genomic and Precision Medicine 185-222.

115. Elemchukwu Q, Obeagu EI, Ochei KC (2014) Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences 9(5): 59-64.

116. Akandinda M, Obeagu EI, Katonera MT (2022) Non-Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics 5(1): 263-267.

117. Gamde MS, Obeagu EI (2023) Iron Deficiency Anaemia: Enemical to Pregnancy. European Journal of

Biomedical 10(9): 272-275.

118. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM (2021) Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International 33(42B): 39-48.

119. Renz H, Brandtzaeg P, Hornef M (2011) The Impact of Perinatal Immune Development on Mucosal Homeostasis and Chronic Inflammation. Nat Rev Immunol 12(1): 9-23.